With an eye on 2026, the healthcare editorial team reflects on key takeaways and trends from recent pharma conferences.
The consolidation comes a week after the vaccine specialist downgraded its 2025 guidance.
The approval enables the use of inavolisib in patients whose cancer has recurred during or after hormone therapy and has metastasised.
Early HIV diagnosis is crucial to maximise health outcomes and ensure the full efficacy of ARTs.
Fucaso's approval in Hong Kong is the first authorisation for a China-developed CAR-T cell therapy.
This licensing deal falls under the biotech’s wider ploy to harness the promise of radiopharmaceuticals within the oncology segment.
